Clinical Trials · NCT06901349
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Withdrawn
- Sponsor
- Eli Lilly and Company
- Enrollment
- 0
- Start date
- May 2025
- Locations
- 50 sites, 5 countries
- Primary endpoint
- Percent Change from Baseline in Body Weight